News
News Release
Cyclomedical Applications Group, LLC
Announces New Associate
Contact: James F. Lamb, Ph.D.
+1-865-670-9021
jlamb@cyclomedical.com
KNOXVILLE, Tennessee,
2006 February 28 —Cyclomedical Applications Group is pleased to announce the appointment of another new Associate, expanding the range of accelerator expertise in positron emission tomography (PET) services and capabilities offered to clients.
Dr. Homer B. Hupf has over forty years experience in the development of cyclotron targetry, radionuclide production, chemical purification and radiopharmaceutical preparation. In both hospital and commercial settings, he has developed production and processing protocols for numerous radionuclides used for clinical studies for both PET and planar imaging. He is well versed in both radiological and USFDA regulatory issues and has been involved in the execution of GMP, DMF, IND and NDA applications. Along with colleagues, he has assisted in facility design for hospital and industry based accelerator radionuclide and radiopharmaceutical production facilities. As an Associate Professor at University of Miami, he has taught nuclear chemistry to graduate students and medical residents. Dr. Hupf has a Ph.D. in Chemistry, is a Registered Pharmacist, and serves as Diplomat of the American Board of Science in Nuclear Medicine.
Dr. James Lamb, President of Cyclomedical, announced, “We are extremely proud to announce the addition of Homer to our team. He is a well known and respected member of the nuclear medicine community, and will be a valuable addition to the group of experts that offer Cyclomedical services.”
Cyclomedical Applications Group is an organization of experienced radiopharmaceutical experts serving the radiopharmaceutical industry, especially owners and operators of medical cyclotrons dedicated to the production of positron emitting radioisotopes. It works primarily with facilities producing and distributing F-18 FDG–the most widely used positron-emitting radiopharmaceutical in PET scanning.
Consulting services offered by the company range from short-term consultation to longer-term retainer arrangements and assistance with regulatory agencies as well as cyclotron operation and FDG production problems. Contract management services range from full responsibility for a cyclotron/FDG production facility to a monitoring posture in support of an in-place management team.
Cyclomedical’s goal is to provide a full range of support expertise including FDG market research and development, facility financing, facility planning and operation, licensing and safety, and FDA regulatory issues. The company currently has operational responsibility for several cyclotron/FDG facilities and is providing cyclotron consultation services to a number of cyclotron operating companies. For more information, see the Cyclomedical web site at www.cyclomedical.com.